Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Seokuee Kim"'
Autor:
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae
Publikováno v:
Gut and Liver, Vol 17, Iss 1, Pp 92-99 (2023)
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexl
Externí odkaz:
https://doaj.org/article/031c5badeb3d4a6fa541965019b9a495
Autor:
Sejung Hwang, Jae-Wook Ko, Heechan Lee, Seokuee Kim, Bongtae Kim, Geun Seog Song, Jungryul Kim
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Potassium-competitive acid blocker is a new class of drugs inhibiting gastric acid. It is controversial that vonoprazan showed the inhibitory activities of cytochrome P450 3A4. This study aimed to evaluate the pharmacokinetics (PK) of atorvastatin an
Externí odkaz:
https://doaj.org/article/0ac707387ef145729c9ab9d63d8e7a73
Autor:
Deok Yong Yoon, SeungHwan Lee, In-Jin Jang, Myeongjoong Kim, Heechan Lee, Seokuee Kim, Bongtae Kim, Geun Seog Song, Su-jin Rhee
Publikováno v:
Pharmaceutics, Vol 13, Iss 9, p 1489 (2021)
This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of tegoprazan and to predict the drug–drug interaction (DDI) potential between tegoprazan and cytochrome P450 (CYP) 3A4 perpetrators. The PBPK model of tegoprazan was
Externí odkaz:
https://doaj.org/article/8aa6e5a4b6eb431b92e05edbac01cd09
Autor:
Eunsol Yang, Seokuee Kim, Bongtae Kim, Boram Kim, Yechan Kim, Sung Sup Park, Geun Seog Song, Kyung‐Sang Yu, In‐Jin Jang, SeungHwan Lee
Publikováno v:
British Journal of Clinical Pharmacology. 88:3288-3296
Nocturnal acid breakthrough has been considered an unmet need of proton-pump inhibitors. Tegoprazan, a novel potassium-competitive acid blocker, is expected to show improved properties for this unmet need. This study was aimed to compare night-time a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3cc77388a34799a0382cbb9ef05e9a9
https://doi.org/10.1111/bcp.15268
https://doi.org/10.1111/bcp.15268
Autor:
Minkyung Oh, Heechan Lee, Seokuee Kim, Bongtae Kim, Geun Seog Song, Jae-Gook Shin, Jong-Lyul Ghim
Publikováno v:
Translational & Clinical Pharmacology; Jun2023, Vol. 31 Issue 2, p114-123, 10p
Autor:
Jeeyun Lee, Jong Mu Sun, Seokuee Kim, Jin Seok Ahn, Jung-Ryul Kim, Sujong Kim, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Joon Oh Park, Rae O. Han, Myung-Ju Ahn
Publikováno v:
Expert Opinion on Investigational Drugs. 29:1059-1067
We evaluated the tolerability, pharmacokinetics (PK) and preliminary efficacy of KML001, an oral trivalent arsenical, as a monotherapy in patients with advanced solid tumors.With a standard 3 + 3 design for dose-escalation stage, the planned dose lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a1432ff9a1f545d28204d5cf941871
https://doi.org/10.1080/13543784.2020.1804855
https://doi.org/10.1080/13543784.2020.1804855
Autor:
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae
Publikováno v:
Gut and liver.
Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a0896b49fac0bf8197a7caec7d788d0
https://pubmed.ncbi.nlm.nih.gov/36317518
https://pubmed.ncbi.nlm.nih.gov/36317518
Autor:
Su Jin Rhee, Geun Seog Song, Myeongjoong Kim, Heechan Lee, Seunghwan Lee, Seokuee Kim, In Jin Jang, Deok Yong Yoon, Bongtae Kim
Publikováno v:
Pharmaceutics, Vol 13, Iss 1489, p 1489 (2021)
Pharmaceutics
Volume 13
Issue 9
Pharmaceutics
Volume 13
Issue 9
This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of tegoprazan and to predict the drug–drug interaction (DDI) potential between tegoprazan and cytochrome P450 (CYP) 3A4 perpetrators. The PBPK model of tegoprazan was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7cbabb381935d12f282adc1c66a42a5
https://www.mdpi.com/1999-4923/13/9/1489
https://www.mdpi.com/1999-4923/13/9/1489
Publikováno v:
Clinical Therapeutics. 41:2204-2218
Celecoxib is a selective cyclooxygenase-2 inhibitor widely used in patients with osteoarthritis and rheumatoid arthritis. Recently, nonclinical data on the inhibition of human ether-à-go-go-related gene potassium channels by celecoxib were reported,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10bce9fc5be0b642793d30fd94a2f178
https://doi.org/10.1016/j.clinthera.2019.09.004
https://doi.org/10.1016/j.clinthera.2019.09.004
Publikováno v:
Clinical Pharmacology in Drug Development
The objective of study was to compare the pharmacokinetic and safety profiles of a fixed‐dose combination (FDC) formulation of 5/160/20 mg amlodipine/valsartan/atorvastatin with those of separate formulations of a 5/160‐mg amlodipine/valsartan ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdd998a0adf8e03fd1305a472eb587bd
http://europepmc.org/articles/PMC7187173
http://europepmc.org/articles/PMC7187173